Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma

Table 5

Univariate and multivariate analysis results of disease-free and overall survival in patients with carcinoembryonic antigen (CEA) ≥ 2.12 IU/mL.

Factor	Univariate analysis			Multivariate analysis
	HR	95% CI		HR	95% CI
Disease-free survival
EGFR mutation (Ex21 versus Ex19)	4.281	1.138–16.105	0.031	2.705	0.657–11.136	0.168
Tumour size (pT1a versus pT1b versus pT1c)	2.910	1.506–5.623	0.001	2.813	0.551–14.358	0.214
Histology (AIS and MIA versus IAC)	13.031	1.748–97.143	0.012	76752.907	0.000–6.609E256	0.970
Lymphatic metastasis (absent versus present)	4.811	1.926–12.018	0.001	9.748	0.262–362.601	0.217
Pathological stage (stage 0 versus I, II, and IIIA)	1.664	1.054–2.627	0.029	0.772	0.099–6.005	0.804
Overall survival
Tumour size (pT1a versus pT1b versus pT1c)	2.966	1.318–6.674	0.009	3.204	0.989–10.382	0.052
Lymphatic metastasis (absent versus present)	5.216	1.725–15.7737	0.003	2.444	1.044–5.720	0.039

HR: hazard ratio; CI: confidence interval; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IAC: invasive adenocarcinoma. .